INCY: Late-stage pipeline progress and targeted launches position for strong post-2029 growth

Management outlined a strategy focused on advancing a robust late-stage pipeline, targeting $3—$4 billion in core business revenue and 15—20% CAGR through 2035. Key programs in oncology and rare diseases are progressing, with major data updates and regulatory milestones expected in the coming month…